STOCK TITAN
  1. Home
  2. Sec-filings
  3. TRAW
  4. [8-K] Traws Pharma, Inc. Reports Material Event

Traws Pharma (NASDAQ: TRAW) shareholders approve equity plan expansion and warrant share issuances

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Traws Pharma, Inc. reported the results of its 2026 annual stockholder meeting and related governance approvals. Stockholders approved an amendment to the 2021 Incentive Compensation Plan that increases the shares available for equity awards by 2,000,000, effective July 8, 2026. They also re-elected seven directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, and approved the issuance of common shares upon exercise of Series B and Series C warrants issued under an April 15, 2026 Securities Purchase Agreement, as required by Nasdaq Listing Rule 5635(d). A proposal to permit adjournment of the meeting, if needed, was approved but not used because all key proposals passed.

Positive

  • None.

Negative

  • None.

Insights

Traws gained stockholder approval for added equity incentives and warrant share issuances.

The meeting confirms broad support for Traws Pharma's board and compensation framework. Stockholders approved adding 2,000,000 shares to the 2021 Incentive Compensation Plan, giving the company more capacity to grant stock-based awards for retention and hiring.

They also approved issuing common shares on exercise of Series B and Series C warrants tied to an April 15, 2026 Securities Purchase Agreement, satisfying Nasdaq Listing Rule 5635(d) requirements. Auditor ratification and the unused adjournment authority indicate routine governance outcomes, with future impact depending on actual equity grants and warrant exercises.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Incentive Plan Increase 2,000,000 shares Additional common shares available under 2021 Incentive Compensation Plan, approved July 8, 2026
Shares Outstanding 15,150,669 shares Common stock issued and outstanding as of May 18, 2026 record date
Shares Represented at Meeting 8,452,410 shares (55.78%) Shares entitled to vote represented by proxy or virtually at annual meeting
Proposal 2 Vote For 4,821,796 votes Votes in favor of incentive plan amendment; 1,694,075 against, 6,690 abstentions
Auditor Ratification For 7,659,805 votes Votes in favor of KPMG LLP as auditor; 789,757 against, 2,848 abstentions
Proposal 4 For 2,270,414 votes Votes in favor of Series B and C warrant share issuance; 151,196 against, 614,528 abstentions
Excluded Shares on Proposal 4 3,486,423 shares Shares excluded from voting on Proposal 4 under Nasdaq listing rules
Adjournment Proposal For 7,882,130 votes Votes in favor of potential meeting adjournment; 562,323 against, 7,957 abstentions
2021 Incentive Compensation Plan financial
"the Company’s stockholders approved an amendment to the Company’s 2021 Incentive Compensation Plan"
Nasdaq Listing Rule 5635(d) regulatory
"To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares"
Nasdaq Listing Rule 5635(d) is a stock-exchange rule that determines when a company must get shareholder approval before issuing new shares tied to conversions or exercises of existing convertible securities, options or warrants. It matters to investors because it controls potential dilution of their holdings and changes in voting power—think of it like a rule that decides whether a previously agreed‑upon coupon can be redeemed without asking the group again.
Series B Warrants financial
"upon exercise of those Series B Warrants and Series C Warrants to purchase shares"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Series C Warrants financial
"Series B Warrants and Series C Warrants to purchase shares of our common stock"
Series C warrants are tradable certificates issued alongside a later-stage financing round that give the holder the right to buy company shares at a fixed price within a set time window. They matter to investors because they can provide low-cost upside if the company’s share price rises, but they can also dilute existing shareholders when converted, similar to a coupon that lets someone buy concert tickets later at today’s price — good for the coupon holder, changing the crowd size and ticket value for everyone else.
Securities Purchase Agreement financial
"pursuant to that certain Securities Purchase Agreement entered into by and between us and such investors on April 15, 2026"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
broker non-votes regulatory
"Votes For | | Votes Against | | Abstentions | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Traws Pharma (TRAW) stockholders approve at the 2026 annual meeting?
Stockholders approved all five proposals at the 2026 annual meeting. They re-elected seven directors, amended the 2021 Incentive Compensation Plan, ratified KPMG LLP as auditor, approved warrant-related share issuances under Nasdaq Rule 5635(d), and authorized potential adjournment, which ultimately was not used.

How many new shares were added to Traws Pharma's 2021 Incentive Compensation Plan?
The plan’s share pool increased by 2,000,000 common shares. Stockholders approved an amendment to the 2021 Incentive Compensation Plan on July 8, 2026, expanding the number of shares available for equity awards and making certain administrative changes, effective immediately after approval.

How many Traws Pharma shares were outstanding and represented at the 2026 meeting?
There were 15,150,669 shares outstanding on the record date. At the meeting, 8,452,410 shares entitled to vote were represented by proxy or virtually, which the company states was approximately 55.78%, establishing a valid quorum for conducting business.

Who is Traws Pharma's independent auditor for the year ending December 31, 2026?
KPMG LLP was ratified as independent registered public accounting firm. Stockholders approved the ratification for the fiscal year ending December 31, 2026, with 7,659,805 votes for, 789,757 against, and 2,848 abstentions, and no broker non-votes on this proposal.

Were all Traws Pharma shareholders allowed to vote on Proposal 4 at the 2026 meeting?
Certain shareholders could not vote on Proposal 4 under Nasdaq rules. Shares issued under an April 15, 2026 Securities Purchase Agreement, totaling 3,486,423, were excluded from voting on the warrant issuance proposal in accordance with Nasdaq listing requirements.
false 0001130598 0001130598 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 8, 2026

 

Traws Pharma, Inc.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-36020   22-3627252
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

12 Penns Trail

Newtown, PA 18940
(267) 759-3680

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $.01 per share TRAW The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As described in Item 5.07 below, on July 8, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Traws Pharma, Inc. (the “Company”), the Company’s stockholders approved an amendment to the Company’s 2021 Incentive Compensation Plan (as so amended, the “Plan”), to increase the number of shares of common stock available for issuance by 2,000,000 and make certain other administrative changes (the “Amendment”). The amendment to the Plan became effective on July 8, 2026 following receipt of stockholder approval.

 

Additional information regarding the Plan is set forth in the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”) filed by the Company with the Securities and Exchange Commission on May 29, 2026, which information is incorporated herein by reference. Such information and the foregoing description of the Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Amendment, a copy of which is attached to this Current Report Exhibit 10.1 and is incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On July 8, 2026, the Company held the Annual Meeting in a virtual format. At the close of business on May 18, 2026, the record date for the Annual Meeting, there were 15,150,669 shares of Company common stock issued and outstanding, which constituted all of the issued and outstanding shares of capital stock of the Company entitled to vote at the Annual Meeting. Pursuant to Nasdaq listing rules, holders of outstanding shares of the Company’s common stock, as of the Record Date, which were issued to certain investors pursuant to that certain Securities Purchase Agreement entered into by and between us and such investors on April 15, 2026, were not entitled to vote such shares on Proposal No. 4 presented to stockholders for approval at the Annual Meeting. At the Annual Meeting, 8,452,410 of the Company’s 15,150,669 outstanding shares of common stock entitled to vote as of the record date, or approximately 55.78%, were represented by proxy or in person (virtually), and, therefore, a quorum was present.

 

The proposals voted on at the Annual Meeting are more fully described in the Proxy Statement, which information is incorporated herein by reference.

 

The final voting results on the proposals presented for stockholder approval at the Annual Meeting were as follows:

 

Proposal 1: To elect seven directors, each to hold office until our 2027 Annual Meeting of Stockholders and until his or her successor is elected and qualified. Each nominee for director was elected by a vote of the stockholders as follows:

 

Nominee   Votes For   Withheld   Broker Non-Votes
Iain Dukes, D.Phil.   6,448,795   73,766   1,929,849
Werner Cautreels, Ph.D.   6,448,941   73,620   1,929,849
Trafford Clarke, Ph.D.   5,711,434   811,127   1,929,849
John Leaman, M.D.   6,466,029   56,532   1,929,849
Nikolay Savchuck Ph.D.   6,448,282   74,279   1,929,849
M. Teresa Shoemaker   5,710,047   812,514   1,929,849
Jack E. Stover   5,694,085   828,476   1,929,849

 

Proposal 2: To consider and vote upon an amendment of the Company’s 2021 Incentive Compensation Plan, as amended and restated, to increase the number of shares of common stock available for issuance by 2,000,000 and make certain other administrative changes. The proposal to approve the Amended Plan was approved by a vote of the stockholders as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
4,821,796   1,694,075   6,690   1,929,849

 

 

 

 

Proposal 3: To consider and vote upon the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal was approved by a vote of the stockholders as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
7,659,805   789,757   2,848   0

 

Proposal 4: To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of shares of our common stock upon exercise of those Series B Warrants and Series C Warrants to purchase shares of our common stock issued to certain investors pursuant to that certain Securities Purchase Agreement entered into by and between us and such investors on April 15, 2026. The proposal was approved by a vote of the stockholders as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
2,270,414   151,196   614,528*   1,929,849

 

* As noted above, excludes an aggregate of 3,486,423 shares from Proposal No. 4, in accordance with Nasdaq listing rules.

 

Proposal 5: To approve the adjournment of the Annual Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in the event we have not received sufficient votes in favor of any of the foregoing proposals. The proposal was approved by a vote of the stockholders as follows:

 

Votes For   Votes Against   Abstentions   Broker Non-Votes
7,882,130   562,323   7,957   0

 

Although Proposal 5 was approved by the Company’s stockholders, the Company did not elect to adjourn the Annual Meeting, as each of Proposals 1 through 4 were approved by the Company’s stockholders.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
10.1   First Amendment to the Traws Pharma, Inc. 2021 Incentive Compensation Plan.
104   Cover Page Interactive Data File (embedded within the inline XBRL Document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 9, 2026 TRAWS PHARMA, INC.
   
  By: /s/ Charles Parker
    Charles Parker
    Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

Other Documents